Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor. It does not require routine monitoring and has been approved by the FDA for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Note, however, that no effective reversal agent for dabigatran in the event of catastrophic hemorrhage has been identified.

via Medical News:Minor Trauma Led to Death in Pradaxa Patient – in Neurology, Head Trauma from MedPage Today.

On the article’s webpage you’ll find a link to download a PDF copy of the source article.